Evidence map›Paper›PMID 38562778›Full record

ArticleResearch square2024

The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies.

Eric Sweet-Cordero, Kieren Marini, Emma Champion, Alex Lee, Isabelle Young, Stanley Leung, Nicolas Mathey-Andrews, Tyler Jacks, Peter Jackson, Jennifer Cochran

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Eric Sweet-CorderoUniversity of California System.ORCID 0000-0002-9787-9351
Kieren MariniDivision of Oncology, Department of Pediatrics, University of California San Francisco.
Emma ChampionDivision of Oncology, Department of Pediatrics, University of California San Francisco.
Alex LeeUniversity of California, San Francisco.
Isabelle YoungDivision of Oncology, Department of Pediatrics, University of California San Francisco.ORCID 0000-0002-0835-4263
Stanley LeungDivision of Oncology, Department of Pediatrics, University of California San Francisco.
Nicolas Mathey-AndrewsMassachussets Institute of Technology.
Tyler JacksDavid H. Koch Institute for Integrative Cancer Research.ORCID 0000-0001-5785-8911
Peter JacksonStanford University School of Medicine.ORCID 0000-0002-1742-2539
Jennifer CochranStanford University.ORCID 0000-0002-6532-9873
University of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher · 2020 to 2026
$4.5M
Development of novel protein-based therapeutics for lung cancerR01CA225103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASSIK, MICHAEL C, COCHRAN, JENNIFER R · 2018 to 2022
$2.8M
Identifying and Targeting Mechanisms for Membrane Signaling in Human CancerR01CA250534 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACKSON, PETER KENT, SWEET-CORDERO, ERIC ALEJANDRO · 2021 to 2025
$2.7M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA225103NCI NIH HHS R01 CA250534NIGMS NIH HHS T32 GM136547NIH HHS S10 OD028511
6 · The paper itself

Abstract

Tumors comprise a complex ecosystem consisting of many cell types that communicate through secreted factors. Targeting these intercellular signaling networks remains an important challenge in cancer research. Cardiotrophin-like cytokine factor 1 (CLCF1) is an interleukin-6 (IL-6) family member secreted by cancer-associated fibroblasts (CAFs) that binds to ciliary neurotrophic factor receptor (CNTFR), promoting tumor growth in lung and liver cancer

Identifiers

PMID38562778
PMCPMC10984090
OpenAlexW4393082476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.